Stanley Druckenmiller's Duquesne Family Office Increases Healthcare Stock Holdings
Billionaire Stanley Druckenmiller’s hedge fund, the Duquesne Family Office, has significantly increased its exposure to healthcare stocks. A year ago, these represented about 22% of the portfolio; today they account for over 36%. Natera (NTRA), a cell-free DNA testing company, is now the fund's top holding at around 17%, with additional shares purchased in Q2. Druckenmiller’s strategy focuses on high-conviction biotech and medtech companies with proprietary technology. He favors noncyclical businesses like Natera that benefit from long-term trends such as early cancer detection and regulatory barriers to entry. The fund also added positions in Insmed (INSM) and Rhythm Pharmaceuticals (RYTM), both of which are niche, catalyst-driven biotechs. Natera reported strong Q2 results with 38% year-over-year revenue growth and improved gross margins. It expects full-year revenue to rise by over 300%. Insmed also saw significant revenue gains in the second quarter while narrowing its losses.
Tickers: $INSM $LLY $NTRA $NVO $RYTM
Topics: biotech healthcare hedge_fund_activity